Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-06-25 | New | $8,860,552 | $8,860,552 | Equity Only | 06b | SEC link |
| 2021-01-25 | New | $6,265,647 | $6,265,647 | Equity Only | 06b | SEC link |
| 2015-09-22 | Amended | $34,000,001 | $16,950,001 | Equity Only | 06b | SEC link |
| 2014-07-01 | New | $17,050,000 | $17,050,000 | Equity Only | 06b | SEC link |
| 2013-03-15 | New | $10,736,836 | $10,736,836 | Equity Only | 06 | SEC link |
| Name | Role |
|---|---|
| Gerry Brunk | Director |
| Gerald Brunk | Director |
| David Celermajer | Director |
| Daniel B. Curtis | Executive |
| Dan B. Curtis | Executive |
| George J. Fazio | Director, Executive |
| Uri Geiger | Director |
| Kevin Gillis | Director |
| Paul La Violette | Director |
| Mark Levin | Director |
| Hemant Taneja | Director |
| Irit Yaniv | Director |